Next Phase Newsletter

A private equity firm based in Beijing, China specializes in growth capital and buy-out investment. The firm focuses on growing Chinese and Western companies in several sectors including healthcare that benefit from China’s growing consumption population. The firm invests north of US$20 million in companies in Series B, C, or above. The firm considers opportunities from China as well as overseas deals with a China angle.

Within healthcare, the firm is looking for cutting-edge technologies in biopharmaceuticals, medical devices, diagnostics, and technology platform. The firm typically prefers mature companies. However, the firm is also interested in pre-revenue companies with disruptive technologies that address large unmet needs.

The firm is seeking experienced management teams with strong sector knowledge. The firm may request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Switzerland raised a new fund in 2016. The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 2 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe with a focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health etc. The firm focuses on companies developing biotech platforms, research tools and nutrition in preclinical and clinical stages. The firm will not invest in drug development companies or medical device companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, and technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A $150 million venture capital fund managed on behalf of a not-for-profit health system makes direct investments in innovative healthcare companies. Typical equity allocations range from $5-8 million over the life of a company. The firm typically co-invests with other VC funds but is also open to leading in a financing round. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com